Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 52: 1602-1603, 2006; 10.1373/clinchem.2006.069369
This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fokkema, M. R.
Right arrow Articles by Moecks, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fokkema, M. R.
Right arrow Articles by Moecks, J.
Related Collections
Right arrow Informatics and Statistics
Right arrow Proteomics and Protein Markers
Right arrow Current Issues in Laboratory Medicine
(Clinical Chemistry. 2006;52:1602-1603.)
© 2006 American Association for Clinical Chemistry, Inc.


Letters to the Editor

Reference Change Values for Brain Natriuretic Peptides Revisited

M. Rebecca Fokkema1,a, Zuzana Herrmann2, Frits A.J. Muskiet1 and Joachim Moecks2

1 Pathology and Laboratory Medicine, University Medical Hospital Groningen, Groningen, The Netherlands
2 Roche Diagnostics GmbH, Mannheim, Germany

aAddress correspondence to this author at: University Medical Hospital Groningen, Department of Pathology and Laboratory Medicine, CMC-V, Room Y1.165, PO Box 30.001, 9700 RB Groningen, The Netherlands. E-mail m.r.fokkema{at}lc.umcg.nl.


To the Editor:

In 2004, Bruins et al. (1) published a report in which they used the approach of Harris and Yasaka (2) to determine the reference change values (RCVs) for B-type natriuretic peptide (BNP) and N-terminal proBNP (NT-proBNP). Week-to-week RCVs were 113% and 98%, respectively, meaning that concentrations had to increase or decrease by these percentages to be assessed as different from the previous measurement, with a 5% error probability for falsely assessing a change as significant. The clinical relevance of these large RCVs led to a lively discussion (3)(4)(5)(6) regarding RCV methodology. In response, we have developed some ideas for improving RCV calculation by addressing the skewness of the distribution.

The previous study used for the new approach investigated 43 patients with stable chronic heart failure by within-day, day-to-day, and week-to-week measurements of BNP (Abbott Diagnostics) and NT-proBNP (Elecsys® proBNP, Roche Diagnostics GmbH). For details, see the original report (1).

Natriuretic peptides are secreted in response to increased demand and may not be conceived to fluctuate around a physiologic (homeostatic) set point as do analytes that are regulated by physiologic processes. The assumption of gaussian-distributed measurements may not hold, and indeed, the (interindividual) distribution of natriuretic peptides shows a right-skewed shape. Whereas log-transformation is the recognized remedy for appropriate transformation, its use in the construction of RCVs was not proposed and also requires an intraindividual skewed distribution. Assessing the skewness can be accomplished by comparing the arithmetic mean and median: the mean is greater than the median for right-skewed distributions. The success of log-transformation, based on the raw data from the original report (1), was assessed by determining the percentage deviation from 1 of the week-to-week mean over the week-to-week median, before and after transformation. Mean deviations before and after transformation were 10.6% and –0.1% for BNP and 10.3% and 0.5% for NT-proBNP, respectively. These results suggest that a lognormal approach is preferable over a normal approach for BNP and NT-proBNP. Measurements follow a lognormal distribution if the logarithms of the measurements follow a gaussian distribution.

Mathematically, the lognormal distribution uses 2 parameters, µ and {varsigma}2, the mean and variance of the underlying gaussian distribution. The lognormal mean, SD, and the CV are determined by µ and {varsigma}2:

In the following derivation of RCVs, only the total variation is considered [no split in subcomponents; for a comparison, see Ref. (7)]. A change between 2 consecutive (independent) measurements, x and y, is considered significant (with 5% error probability) when the difference,

Formula
exceeds ± Formula x z x {varsigma}, where z = 1.96. This follows from the gaussian distribution of the log-transformed measurements [compare with Iglesias et al. (8)]. By retransforming the difference and the interval borders to the original scale, we see that

Formula
must be outside of [exp{–1.96 x Formula x {varsigma}}; exp{+1.96 x Formula x {varsigma}}] to be significant. Because

Formula
the RCVs for the relative difference in percentages can be easily derived from the above borders. Note that these RCVs are nonsymmetric—they differ for increases or decreases—and that implausible decreases of 100% or more are not possible, an obvious advantage over the standard calculation.

Turning this approach to practice requires an estimate Formula of the parameter {varsigma}. A simple way can be based on aggregate data. Because the lognormal CV depends only on {varsigma} (see the scheme ), this yields {varsigma} = Formula. Thus, Formula can be obtained by inserting the untransformed population CV in this expression, and the derivation of RCVs can proceed as delineated above. The results are compiled in Table 1 . We note that an estimate of {varsigma} can also be based on the single serial measurements given in the original study (1), which lead to very similar RCVs. A statistical article discussing several options for RCVs in skewed distributions is in preparation.


Figure 1
View larger version (5K):
[in this window]
[in a new window]
 
Figure 1. Scheme 1.


View this table:
[in this window]
[in a new window]
 
Table 1. Comparison of RCVs calculated according to the lognormal and standard approaches.1

The lognormal RCVs possess better biological plausibility. Paradoxical values of decreases greater than 100% are eliminated. However, in view of monitoring applications, these RCVs are still rather high. The corrected lognormal RCVs refer to the commonly used 5% bidirectional statistical error. This RCV setup implies that ~5% of clinically stable patients show changes greater than the RCV (false positives). However, for the treatment of heart failure, false negatives present the major risk, and it is imperative that deterioration in a patient’s clinical condition is not missed so that appropriate clinical intervention can be initiated (9). The common probability "insurance" of 95% against false positives could be too high, and another value, 80%, would be clinically more appropriate to lower the false-negative rate. When 80% is used in the construction of RCVs, then NT-proBNP week-to-week lognormal RCVs narrow to 85% for increases and to –46% for decreases.

The important message we take from this analysis is that the skewness of the distribution requires adequate methods to deal with it to achieve clinically and biologically valid RCVs.


References

  1. Bruins S, Fokkema MR, Romer JW, Dejongste MJL, van der Dijs FPL, van den Ouweland JM, et al. High intraindividual variation of B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with stable chronic heart failure. Clin Chem 2004;50:2052-2058.[Abstract/Free Full Text]
  2. Harris EK, Yasaka T. On the calculation of a "reference change" for comparing two consecutive measurements. Clin Chem 1983;29:25-30.[Abstract/Free Full Text]
  3. Prontera C, Emdin M, Zucchelli GC, Ripoli A, Passino C, Clerico A. Analytical performance and diagnostic accuracy of a fully-automated electrochemiluminescent assay for the N-terminal fragment of the pro-peptide of brain natriuretic peptide in patients with cardiomyopathy: comparison with immunoradiometric assay methods for brain natriuretic peptide and atrial natriuretic peptide. Clin Chem Lab Med 2004;42:37-44.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  4. Clerico A, Zucchelli GC, Pilo A, Emdin M. Clinical relevance of biological variation of B-type natriuretic peptide. Clin Chem 2005;51:925-926.[Free Full Text]
  5. Apple FS, Panteghini M, Ravkilde J, Mair J, Wu AH, Tate J, et al. Quality specifications for B-type natriuretic peptide assays. Clin Chem 2005;51:486-493.[Abstract/Free Full Text]
  6. Fraser CG. Quality specifications for imprecision of B-type natriuretic peptide assays. Clin Chem 2005;51:1307-1309.[Free Full Text]
  7. Fraser CG. Biological Variation: From Principles to Practice 2001:67-70 AACC Press Washington. .
  8. Iglesias N, Petersen PH, Ricos C. Power function of the reference change value in relation to cut-off points, reference intervals and index of individuality. Clin Chem Lab Med 2005;43:441-448.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  9. Clerico A, Zucchelli CG, Pilo A, Passino C, Emdin M. Clinical relevance of biological variation: the lesson of brain natriuretic peptide (BNP) and NT-proBNP assay. Clin Chem Lab Med 2006;44:366-378.[CrossRef][ISI][Medline] [Order article via Infotrieve]



The following articles in journals at HighWire Press have cited this article:


Home page
CirculationHome page
F. S. Apple, A. H.B. Wu, A. S. Jaffe, M. Panteghini, R. H. Christenson, NACB COMMITTEE MEMBERS, R. H. Christenson, F. S. Apple, C. P. Cannon, G. Francis, et al.
National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: Analytical Issues for Biomarkers of Heart Failure
Circulation, July 31, 2007; 116(5): e95 - e98.
[Full Text] [PDF]


This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fokkema, M. R.
Right arrow Articles by Moecks, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fokkema, M. R.
Right arrow Articles by Moecks, J.
Related Collections
Right arrow Informatics and Statistics
Right arrow Proteomics and Protein Markers
Right arrow Current Issues in Laboratory Medicine


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS